Plain-English translation of NCT05653232 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing sofosbuvir/velpatasvir, a combination medication that cures hepatitis C in nearly all patients. Kidneys from donors with hepatitis C can now safely be given to recipients without the disease because of drugs like this one. The study compares two ways of giving this medication: starting it before the transplant for a short time, or starting it after the transplant for a longer time.
Both approaches have successfully prevented hepatitis C infection in recipients, but doctors don't yet know which timing strategy is best. This trial will help determine whether the shorter course given before transplant works just as well as the longer course given after transplant.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to one of two groups. One group will start taking the medication about 2 weeks before the transplant and continue for 2 weeks after. The other group will start the medication within 2 weeks after the transplant and take it for 12 weeks. You will have blood tests and regular visits to monitor how well the medication works and how you're recovering from your transplant.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States